A Novel Nomogram for Predicting Cancer-Specific Survival in Patients With Spinal Chordoma: A Population-Based Analysis.
Epidemiology
Surveillance
and End Results
cancer-specific survival
nomogram
spinal chordoma
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
12
8
2021
pubmed:
13
8
2021
medline:
10
2
2022
Statut:
ppublish
Résumé
Chordoma is a rare malignant bone tumor, and the survival prediction for patients with chordoma is difficult. The objective of this study was to construct and validate a nomogram for predicting cancer-specific survival (CSS) in patients with spinal chordoma. A total of 316 patients with spinal chordoma were identified from the SEER database between 1998 and 2015. The independent prognostic factors for patients with spinal chordoma were determined by univariate and multivariate Cox analyses. The prognostic nomogram was established for patients with spinal chordoma based on independent prognostic factors. Furthermore, we performed internal and external validations for this nomogram. Primary site, disease stage, histological type, surgery, and age were identified as independent prognostic factors for patients with spinal chordoma. A nomogram for predicting CSS in patients with spinal chordoma was constructed based on the above 5 variables. In the training cohort, the area under the curve for predicting 1-, 3-, and 5-year CSS were 0.821, 0.856, and 0.920, respectively. The corresponding area under the curve in the validation cohort were 0.728, 0.804, and 0.839, respectively. The calibration curves of the nomogram showed a high degree of agreement between the predicted and the actual results, and the decision curve analysis further demonstrated the satisfactory clinical utility of the nomogram. The prognostic nomogram provides a considerably more accurate prediction of prognosis for patients with spinal chordoma. Clinicians can use it to categorize patients into different risk groups and make personalized treatment methods.
Sections du résumé
BACKGROUND
Chordoma is a rare malignant bone tumor, and the survival prediction for patients with chordoma is difficult. The objective of this study was to construct and validate a nomogram for predicting cancer-specific survival (CSS) in patients with spinal chordoma.
METHODS
A total of 316 patients with spinal chordoma were identified from the SEER database between 1998 and 2015. The independent prognostic factors for patients with spinal chordoma were determined by univariate and multivariate Cox analyses. The prognostic nomogram was established for patients with spinal chordoma based on independent prognostic factors. Furthermore, we performed internal and external validations for this nomogram.
RESULTS
Primary site, disease stage, histological type, surgery, and age were identified as independent prognostic factors for patients with spinal chordoma. A nomogram for predicting CSS in patients with spinal chordoma was constructed based on the above 5 variables. In the training cohort, the area under the curve for predicting 1-, 3-, and 5-year CSS were 0.821, 0.856, and 0.920, respectively. The corresponding area under the curve in the validation cohort were 0.728, 0.804, and 0.839, respectively. The calibration curves of the nomogram showed a high degree of agreement between the predicted and the actual results, and the decision curve analysis further demonstrated the satisfactory clinical utility of the nomogram.
CONCLUSIONS
The prognostic nomogram provides a considerably more accurate prediction of prognosis for patients with spinal chordoma. Clinicians can use it to categorize patients into different risk groups and make personalized treatment methods.
Identifiants
pubmed: 34382474
doi: 10.1177/15330338211036533
pmc: PMC8366201
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15330338211036533Références
Pathology. 2014 Feb;46(2):95-104
pubmed: 24378391
Lancet Oncol. 2015 Apr;16(4):e173-80
pubmed: 25846097
Neuro Oncol. 2015 May;17(5):725-32
pubmed: 25488908
Clin Neurol Neurosurg. 2020 Oct;197:106174
pubmed: 32889324
Blood. 2007 Jun 1;109(11):4679-85
pubmed: 17299097
J Clin Oncol. 2007 Apr 10;25(11):1316-22
pubmed: 17416852
Spine (Phila Pa 1976). 2016 Oct 15;41 Suppl 20:S186-S192
pubmed: 27509195
J Gen Intern Med. 1993 Dec;8(12):702-11
pubmed: 8120690
Neurosurg Rev. 2019 Jun;42(2):455-462
pubmed: 29732516
Cancer Causes Control. 2001 Jan;12(1):1-11
pubmed: 11227920
Lancet Oncol. 2015 Feb;16(2):e71-83
pubmed: 25638683
World Neurosurg. 2018 May;113:e618-e627
pubmed: 29486315
J Neurosurg Spine. 2018 Apr;28(4):422-428
pubmed: 29393831
World Neurosurg. 2015 Nov;84(5):1354-61
pubmed: 26115803
Cancer. 2000 May 1;88(9):2122-34
pubmed: 10813725
Spine (Phila Pa 1976). 2011 May 1;36(10):E656-61
pubmed: 21217422
World Neurosurg. 2017 Aug;104:346-355
pubmed: 28457925
J Orthop Surg Res. 2018 Apr 6;13(1):76
pubmed: 29625617
Am J Surg Pathol. 2017 Mar;41(3):405-413
pubmed: 28195881
Spine (Phila Pa 1976). 1996 Jul 1;21(13):1569-77
pubmed: 8817786
Cancer. 2013 Jun 1;119(11):2029-37
pubmed: 23504991
Eur J Surg Oncol. 2014 Nov;40(11):1412-20
pubmed: 24793103
J Bone Joint Surg Br. 2008 May;90(5):652-6
pubmed: 18450635